Literature DB >> 17935162

Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Marcel R Zurflüh1, Johannes Zschocke, Martin Lindner, François Feillet, Céline Chery, Alberto Burlina, Raymond C Stevens, Beat Thöny, Nenad Blau.   

Abstract

Mutations in the phenylalanine hydroxylase (PAH) gene result in phenylketonuria (PKU). Tetrahydrobiopterin (BH(4))-responsive hyperphenylalaninemia has been recently described as a variant of PAH deficiency caused by specific mutations in the PAH gene. It has been suggested that BH(4)-responsiveness may be predicted from the corresponding genotypes. Data from BH(4) loading tests indicated an incidence of BH(4)-responsiveness of >40% in the general PKU population and >80% in mild PKU patients. The current project entailed genotype analysis of 315 BH(4)-responsive patients tabulated in the BIOPKUdb database and comparison with the data from the PAHdb locus-specific knowledgebase, as well as with previously published PAH mutations for several European countries, Northern China, and South Korea. We identified 57 mutations, presenting with a substantial residual PAH activity (average approximately 47%), presumed to be associated with BH(4)-responsiveness. More than 89% of patients are found to be compound heterozygotes. The three most common mutations found in >5% of BH(4)-responsive patients are p.A403 V, p.R261Q, and p.Y414C. Using the Hardy-Weinberg formula the predicted average frequency of BH(4)-responsiveness in European populations was calculated to be 55% (range 17-79%, lowest in Baltic countries and Poland and highest in Spain), 57% in Northern China, and 55% for South Korea. The genotype-predicted prevalence of BH(4)-responsiveness was higher than prevalence data obtained from BH(4) loading tests. Inconsistent results were observed for mutations p.L48S, p.I65 T, p.R158Q, p.R261Q, and p.Y414C. Our data suggest that BH(4)-responsiveness may be more common than assumed and to some extent may be predicted or excluded from the patient's genotype. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17935162     DOI: 10.1002/humu.20637

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  46 in total

1.  Molecular Genetics and Genotype-Based Estimation of BH4-Responsiveness in Serbian PKU Patients: Spotlight on Phenotypic Implications of p.L48S.

Authors:  Maja Djordjevic; Kristel Klaassen; Adrijan Sarajlija; Natasa Tosic; Branka Zukic; Bozica Kecman; Milena Ugrin; Vesna Spasovski; Sonja Pavlovic; Maja Stojiljkovic
Journal:  JIMD Rep       Date:  2012-10-13

2.  Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

Authors:  M L Couce; M D Bóveda; E Valerio; A Pérez-Muñuzuri; J M Fraga
Journal:  JIMD Rep       Date:  2011-09-06

Review 3.  Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria.

Authors:  Sandra C van Calcar; Denise M Ney
Journal:  J Acad Nutr Diet       Date:  2012-08       Impact factor: 4.910

Review 4.  Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.

Authors:  Ania C Muntau; João Leandro; Michael Staudigl; Felix Mayer; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2014-04-01       Impact factor: 4.982

5.  Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria.

Authors:  F K Trefz; D Scheible; H Götz; G Frauendienst-Egger
Journal:  J Inherit Metab Dis       Date:  2008-10-30       Impact factor: 4.982

6.  Metabolic phenotypes of phenylketonuria. Kinetic and molecular evaluation of the Blaskovics protein loading test.

Authors:  U Langenbeck; P Burgard; U Wendel; M Lindner; J Zschocke
Journal:  J Inherit Metab Dis       Date:  2009-07-16       Impact factor: 4.982

7.  Utility of phenylalanine hydroxylase genotype for tetrahydrobiopterin responsiveness classification in patients with phenylketonuria.

Authors:  Meghan E Quirk; Steven F Dobrowolski; Benjamin E Nelson; Bradford Coffee; Rani H Singh
Journal:  Mol Genet Metab       Date:  2012-07-20       Impact factor: 4.797

8.  Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: assessing responsiveness in a model of statistical process control.

Authors:  M Lindner; G Gramer; S F Garbade; P Burgard
Journal:  J Inherit Metab Dis       Date:  2009-06-10       Impact factor: 4.982

9.  New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride.

Authors:  Cary O Harding
Journal:  Biologics       Date:  2010-08-09

10.  The Missense p.S231F phenylalanine hydroxylase gene mutation causes complete loss of enzymatic activity in vitro.

Authors:  Maja Stojiljkovic; Belén Pérez; Lourdes R Desviat; Cristina Aguado; Magdalena Ugarte; Sonja Pavlovic
Journal:  Protein J       Date:  2009-08       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.